American Association for Cancer Research
crc-23-0264_fig2.png (631.14 kB)

FIGURE 2 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling

Download (631.14 kB)
posted on 2024-02-06, 14:20 authored by Daiki Kanaoka, Mitsuo Yamada, Hironori Yokoyama, Satoko Nishino, Naoshi Kunimura, Hiroshi Satoyoshi, Shota Wakabayashi, Kazunori Urabe, Takafumi Ishii, Masato Nakanishi

Antiproliferative activity of FPFT-2216 via CK1α degradation. FPFT-2216 degrading activity and growth inhibition in Z-138 (A), RS4;11 (B), and RI-1 (C) cells with a CK1α G40N mutant. Left: Western blot analysis of cells cultured for 6 hours (A and B) or 24 hours (C) in the presence of compounds at different concentrations. Representative results from two independent experiments are shown. GAPDH was used as a loading control. Right: Viability (%) of each cell type cultured for three days in the presence of 0.001–100 µmol/L FPFT-2216. Results are presented as the mean ± SD (n = 3). 2216, FPFT-2216; Lena, lenalidomide; Iber, iberdomide.





Reducing casein kinase 1α (CK1α) expression inhibits the growth of multiple cancer cell lines, making it a potential therapeutic target for cancer. Herein, we evaluated the antitumor activity of FPFT-2216—a novel low molecular weight compound—in lymphoid tumors and elucidated its molecular mechanism of action. In addition, we determined whether targeting CK1α with FPFT-2216 is useful for treating hematopoietic malignancies. FPFT-2216 strongly degraded CK1α and IKAROS family zinc finger 1/3 (IKZF1/3) via proteasomal degradation. FPFT-2216 exhibited stronger inhibitory effects on human lymphoma cell proliferation than known thalidomide derivatives and induced upregulation of p53 and its transcriptional targets, namely, p21 and MDM2. Combining FPFT-2216 with an MDM2 inhibitor exhibited synergistic antiproliferative activity and induced rapid tumor regression in immunodeficient mice subcutaneously transplanted with a human lymphoma cell line. Nearly all tumors in mice disappeared after 10 days; this was continuously observed in 5 of 7 mice up to 24 days after the final FPFT-2216 administration. FPFT-2216 also enhanced the antitumor activity of rituximab and showed antitumor activity in a patient-derived diffuse large B-cell lymphoma xenograft model. Furthermore, FPFT-2216 decreased the activity of the CARD11/BCL10/MALT1 (CBM) complex and inhibited IκBα and NFκB phosphorylation. These effects were mediated through CK1α degradation and were stronger than those of known IKZF1/3 degraders. In conclusion, FPFT-2216 inhibits tumor growth by activating the p53 signaling pathway and inhibiting the CBM complex/NFκB pathway via CK1α degradation. Therefore, FPFT-2216 may represent an effective therapeutic agent for hematopoietic malignancies, such as lymphoma. We found potential vulnerability to CK1α degradation in certain lymphoma cells refractory to IKZF1/3 degraders. Targeting CK1α with FPFT-2216 could inhibit the growth of these cells by activating p53 signaling. Our study demonstrates the potential therapeutic application of CK1α degraders, such as FPFT-2216, for treating lymphoma.